Gaush Meditech Ltd (Stock Code: 2407) announced that its subsidiary, Gaush Tech Ltd. (深圳高視科技有限公司), has received a medical device registration certificate from the Guangdong Provincial Medical Products Administration for its “ophthalmic electrophysiological diagnostic system.”

The newly approved system (Registration Certificate No.: Yue Xie Zhu Zhun 20252161439) integrates Visual Evoked Potential (VEP), Electroretinography (ERG), and Electrooculography (EOG) functionalities. VEP assesses the optic nerve’s electrophysiological status, serving as an objective tool when subjective visual acuity tests are not feasible. ERG focuses on retinal function, particularly photoreceptors and bipolar cells, while EOG evaluates the retinal pigment epithelium and photoreceptors.

According to the announcement, this ophthalmic electrophysiological diagnostic system offers non-invasive, quantifiable, and repeatable measurements of bioelectrical changes in the visual pathway. It can detect disorders affecting the optic nerve and retina at early stages, supporting differential diagnoses of conditions such as retinitis pigmentosa and providing an objective assessment of patient outcomes.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of Gaush Meditech Ltd.